JPMorgan Chase & Co. Initiates Coverage on Intersect ENT (XENT)
Analysts at JPMorgan Chase & Co. began coverage on shares of Intersect ENT (NASDAQ:XENT) in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. The firm set an “overweight” rating on the stock.
XENT has been the subject of a number of other recent research reports. Analysts at Leerink Swann initiated coverage on shares of Intersect ENT in a research note on Monday. They set an “outperform” rating on the stock. Analysts at Piper Jaffray initiated coverage on shares of Intersect ENT in a research note on Monday. They set an “overweight” rating on the stock.
Intersect ENT (NASDAQ:XENT) opened at 15.05 on Monday. Intersect ENT has a one year low of $12.02 and a one year high of $15.77. The stock has a 50-day moving average of $13.24 and a 200-day moving average of $13.24. The company’s market cap is $338.6 million.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.